Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Gross Margin for 6 years, with the latest figure at 90.29% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 326.0% year-over-year to 90.29%; the trailing twelve-month figure through Mar 2026 stood at 89.31% (up 348.0% YoY), and the FY2025 full-year result was 88.54%, up 293.0% from the prior year.
• Gross Margin for Q1 2026 stood at 90.29%, up from 89.64% in the prior quarter.
• The five-year high for Gross Margin was 104.52% in Q4 2022, with the low at 81.35% in Q2 2022.
• Historically, Gross Margin has averaged 89.16% across 5 years, with a median of 88.51% in 2023.
• The largest YoY upside for Gross Margin was 1588 bps in 2022 against a maximum downside of 1894 bps in 2022.
• Kiniksa Pharmaceuticals International's Gross Margin stood at 104.52% in 2022, then decreased by 15 bps to 88.51% in 2023, then declined by 4 bps to 85.4% in 2024, then increased by 5 bps to 89.64% in 2025, then gained by 1 bps to 90.29% in 2026.
• The last three Gross Margin figures came in at 90.29% (Q1 2026), 89.64% (Q4 2025), and 88.8% (Q3 2025), per Business Quant data.